Related Experiment Video
Updated: Jan 31, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Resistance to Second-Generation HIV-1 Maturation Inhibitors
Emiko Urano1, Uddhav Timilsina2, Justin A Kaplan1
1Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
New HIV-1 maturation inhibitors show potent activity against resistant strains. Researchers identified specific mutations conferring resistance, offering insights into drug mechanisms and guiding future HIV-1 treatment development.
Area of Science:
- Virology
- Drug Discovery
- Molecular Biology
Background:
- Bevirimat (BVM), a betulinic acid-based compound, inhibits HIV-1 maturation by blocking Gag polyprotein processing, specifically the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate.
- Resistance to BVM emerged due to mutations near the CA-SP1 cleavage site, leading to the discontinuation of its clinical development.
- Second-generation BVM analogs have been developed with improved potency and broader activity against HIV-1.
Purpose of the Study:
- To investigate the efficacy of second-generation bevirimat analogs against HIV-1 strains with existing BVM resistance mutations.
- To identify novel mutations conferring resistance to these advanced maturation inhibitors through de novo selection experiments.
- To gain insights into the mechanisms of resistance to second-generation HIV-1 maturation inhibitors.
Main Methods:
- Performed de novo selection experiments using subtype B and subtype C HIV-1 to identify resistance mutations to second-generation bevirimat analogs.
- Sequenced viral clones to pinpoint specific amino acid substitutions in Gag (SP1 and CA domains) associated with resistance.
- Assessed the impact of identified mutations on HIV-1 susceptibility to maturation inhibitors and analyzed CA-SP1 processing kinetics.
Main Results:
- Second-generation BVM analogs effectively inhibited viral clones with BVM resistance mutations near the C terminus of CA.
- Resistance mutations identified in subtype B included SP1-A1V and CA-P157A; in subtype C, mutations included CA-V230M, SP1-A1V, SP1-S5N, and SP1-G10R.
- These resistance-conferring mutations occurred at highly conserved positions within the Gag protein and resulted in modest to high-level resistance, generally without significantly altering CA-SP1 processing kinetics.
Conclusions:
- Second-generation bevirimat analogs demonstrate potent activity against HIV-1 strains resistant to earlier compounds.
- The identified mutations provide a detailed map of resistance mechanisms for novel maturation inhibitors.
- These findings are crucial for understanding HIV-1 resistance pathways and for the rational design of future antiretroviral therapies.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Maturation of Endosomes
Changes in location
The maturing endosome moves along microtubules from the periphery of the cell towards the perinuclear region. This movement of the...
Bacterial Protein Maturation
Resistivity
Resistance
Equivalent Resistance

